O'Donnell: better to come from Smith & Nephew in H2
This article was originally published in Clinica
Executive Summary
Smith & Nephew CEO Chris O'Donnell last week said that impressive first-half 2002 sales gain of 18% (including 4% from acquisitions) would be bettered in the second half on the strength of sound growth in its three core businesses. Endoscopy (sales rise 14%), orthopaedics (20%) and wound management (18%) all contributed to first- half sales of $551m ($827m). Analysts said the overall growth was 2% higher than consensus targets.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.